Navigation Links
Researchers identify new compound to treat depression
Date:6/17/2014

There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug, according to a study in the July issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists (ASA). Interestingly, use of HNK may also serve as a future therapeutic approach for treating neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, the authors note.

"The clinical use of ketamine therapy for depression is limited because the drug is administered intravenously and may produce adverse effects such as hallucinations and sedation to the point of anesthesia," said Irving Wainer, Ph.D., senior investigator with the Intramural Research Program at the National Institute on Aging, Baltimore. "We found that the HNK compound significantly contributes to the anti-depressive effects of ketamine in animals, but doesn't produce the sedation or anesthesia, which makes HNK an attractive alternative as an antidepressant in humans."

HNK is one of several different compounds produced when ketamine, an anesthesia medicine-turned-antidepressant, is broken down (metabolized) in the body. Using a rat model, researchers tested HNK to see if the compound alone could produce the same beneficial effects attributed to ketamine without ketamine's unwanted side effects.

In the study, rats were given intravenous doses of ketamine, HNK and another compound produced by ketamine metabolism known as norketamine. The effect each had on stimulating certain cellular pathways of the rats' brains was examined after 20, 30 and 60 minutes. Brain tissue from drug-free rats was used as a control.

Researchers found the compound HNK, like ketamine, not only produced potent and rapid antidepressant effects, but also stimulated neuro-regenerative pathways and initiated the regrowth of neurons in rats' brains. HNK also appears to have several advantages over ketamine in that it is 1,000 times more potent, does not act as an anesthetic agent, and can be taken by mouth, the authors report.

Surprisingly, HNK was also found to reduce the production of D-serine, a chemical found in the body, overproduction of which is associated with neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. HNK's ability to reduce the production of D-serine, while stimulating the regeneration of neuron connections in the brain, may present a potential new therapeutic approach to the treatment of these disorders.


'/>"/>
Contact: Theresa Hill
t.hill@asahq.org
847-268-9246
American Society of Anesthesiologists
Source:Eurekalert  

Related medicine news :

1. Researchers create better methods to detect E. coli
2. UGA researchers discover new method to reduce disease-causing inflammation
3. Ottawa researchers key to new neuromuscular disease care and research network
4. Researchers uncover new insights into developing rapid-acting antidepressant for treatment-resistant depression
5. Broad Institute, MGH researchers chart cellular complexity of brain tumors
6. Researchers uncover common heart drugs link to diabetes
7. Mayo Clinic researchers discover new form of cancer
8. Researchers recast addiction as a manageable disease
9. Mount Sinai researchers identify protein that keeps blood stem cells healthy as they age
10. Berkeley Lab researchers create nanoparticle thin films that self-assemble in 1 minute
11. Study shows health policy researchers lack confidence in social media for communication
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers identify new compound to treat depression
(Date:5/3/2016)... Los Angeles, CA (PRWEB) , ... May 03, 2016 , ... ... Massage Chair with its user friendly Samsung tablet and exclusive Smart Application. The ... truly unbeatable massage. Starting each massage with a customized user profile and specialized massage ...
(Date:5/3/2016)... ... 03, 2016 , ... Intrigma, the leading provider of vital ... expanding its use of Intrigma’s cloud-based physician scheduling solution, Efficient Scheduler (a part ... The Portland, Oregon based health system conducted a one-year pilot of the Efficient ...
(Date:5/3/2016)... ... May 03, 2016 , ... Octo ... solutions and digital consulting services to the federal government, has been awarded a ... / Indefinite Quantity (ID/IQ) contract in support of the U.S. Army Program Executive ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... a special type of surgical procedure that can be used to diagnose and treat ... instruments can be inserted. These instruments include a special lighting system and lens that ...
(Date:5/3/2016)... ... 2016 , ... Branches, Inc. is proud to have been selected as a ... in South Miami. Macy’s is a wonderful community partner and has helped to support ... mentoring, enrichment and academic support to elementary students 5 days a week. Summer Shade, ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... May 2, 2016  Deerfield announced today it ... Graybug Vision, Inc. Graybug Vision is an early ... may transform care for ocular diseases including wet ... technology was first developed at Johns Hopkins University ... venture. Graybug Vision is developing ...
(Date:5/2/2016)... , May 2, 2016 ... to reach USD 11.1 billion by 2024, according ... Research, Inc. Major drivers of the sonography market ... areas and government recommendations for periodic ultrasound screenings ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
(Date:4/29/2016)... New Jersey , April 29, 2016 /PRNewswire/ ... Software Suite for Life Sciences, Product Development Capabilities ... Global Life Science Customer Base . ... solutions provider, today announced the acquisition of Skura ... a global leader in adaptive sales enablement technology ...
Breaking Medicine Technology: